Spero Therapeutics, Inc. (SPRO) stock
SPRONasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.00−0.00 (-0.01%)
Close on Nov 13, 2026Market cap $58.23MP/E –Yield –
Spero Therapeutics cash
Cash and short-term investments held at the end of each period.
Spero Therapeutics's cash was $107.93M at Sep 30, 2026. For fiscal 2025 it was $40.27M, down 23.9% from the year before. Over ten years it grew 21.6% a year on average. The highest annual figure on record is $146.40M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $40.27M | -23.9% |
| FY2024 | Dec 31, 2024 | $52.89M | -30.7% |
| FY2023 | Dec 31, 2023 | $76.33M | -30.0% |
| FY2022 | Dec 31, 2022 | $109.11M | -25.5% |
| FY2021 | Dec 31, 2021 | $146.40M | +15.4% |
| FY2020 | Dec 31, 2020 | $126.91M | +54.7% |
| FY2019 | Dec 31, 2019 | $82.05M | -28.9% |
| FY2018 | Dec 31, 2018 | $115.44M | +32.3% |
| FY2017 | Dec 31, 2017 | $87.29M | +742.1% |
| FY2016 | Dec 31, 2016 | $10.37M | +82.1% |
| FY2015 | Dec 31, 2015 | $5.69M | +2123.0% |
| FY2014 | Dec 31, 2014 | $256.00K | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $107.93M | +122.0% |
| Q2 FY2026 | Jun 30, 2026 | $50.77M | +62.8% |
| Q1 FY2026 | Mar 31, 2026 | $56.13M | +14.8% |
| Q4 FY2025 | Dec 31, 2025 | $40.27M | -23.9% |
| Q3 FY2025 | Sep 30, 2025 | $48.62M | -36.3% |
| Q2 FY2025 | Jun 30, 2025 | $31.19M | -50.9% |
| Q1 FY2025 | Mar 31, 2025 | $48.89M | -40.6% |
| Q4 FY2024 | Dec 31, 2024 | $52.89M | -30.7% |
| Q3 FY2024 | Sep 30, 2024 | $76.29M | -18.7% |
| Q2 FY2024 | Jun 30, 2024 | $63.53M | -18.2% |
| Q1 FY2024 | Mar 31, 2024 | $82.27M | -14.5% |
| Q4 FY2023 | Dec 31, 2023 | $76.33M | -30.0% |
| Q3 FY2023 | Sep 30, 2023 | $93.83M | +86.0% |
| Q2 FY2023 | Jun 30, 2023 | $77.69M | +71.1% |
| Q1 FY2023 | Mar 31, 2023 | $96.25M | -21.1% |
| Q4 FY2022 | Dec 31, 2022 | $109.11M | -25.5% |
| Q3 FY2022 | Sep 30, 2022 | $50.45M | -59.1% |
| Q2 FY2022 | Jun 30, 2022 | $45.40M | -54.2% |
| Q1 FY2022 | Mar 31, 2022 | $121.97M | +5.4% |
| Q4 FY2021 | Dec 31, 2021 | $146.40M | +15.4% |
| Q3 FY2021 | Sep 30, 2021 | $123.42M | -3.0% |
| Q2 FY2021 | Jun 30, 2021 | $99.22M | +39.0% |
| Q1 FY2021 | Mar 31, 2021 | $115.68M | +30.2% |
| Q4 FY2020 | Dec 31, 2020 | $126.91M | +54.7% |
| Q3 FY2020 | Sep 30, 2020 | $127.24M | +35.6% |
| Q2 FY2020 | Jun 30, 2020 | $71.36M | -31.0% |
| Q1 FY2020 | Mar 31, 2020 | $88.84M | -16.5% |
| Q4 FY2019 | Dec 31, 2019 | $82.05M | -28.9% |
| Q3 FY2019 | Sep 30, 2019 | $93.86M | -28.5% |
| Q2 FY2019 | Jun 30, 2019 | $103.41M | +55.2% |
| Q1 FY2019 | Mar 31, 2019 | $106.39M | +41.1% |
| Q4 FY2018 | Dec 31, 2018 | $115.44M | +32.3% |
| Q3 FY2018 | Sep 30, 2018 | $131.23M | +417.2% |
| Q2 FY2018 | Jun 30, 2018 | $66.64M | +43.7% |
| Q1 FY2018 | Mar 31, 2018 | $75.39M | +627.4% |
| Q4 FY2017 | Dec 31, 2017 | $87.29M | – |
| Q3 FY2017 | Sep 30, 2017 | $25.37M | – |
| Q1 FY2017 | Mar 31, 2017 | $46.39M | – |
| Q4 FY2016 | Dec 31, 2016 | $10.37M | – |
See a number that looks wrong?